Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

10 results
Display

Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers

Liang LY, Wong VWS, Wong GLH, Yip TCF

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact

Yip TCF, Wong GLH, Wong VWS

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Dipeptidyl peptidase-4 inhibitors are associated with improved survival of patients with diabetes mellitus and hepatocellular carcinoma receiving immunotherapy: Letter to the editor on “Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?”

Yiu DCY, Lin H, Wong VWS, Wong GLH, Liu K, Yip TCF

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Drug-drug interactions with direct-acting antivirals — less is more

Wong GLH

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Unlocking the future: Machine learning sheds light on prognostication for early-stage hepatocellular carcinoma: Editorial on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”

Dai J, Lai JCT, Wong GLH, Yip TCF

CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Application of transient elastography in nonalcoholicfatty liver disease

Zhang X, Wong GLH, Wong VWS

Nonalcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide. Although it has become one of the leading causes of cirrhosis and hepatocellular carcinoma in the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Yip TCF, Lyu F, Lin H, Li G, Yuen PC, Wong VWS, Wong GLH

Inflammation is the key driver of liver fibrosis progression in non-alcoholic fatty liver disease (NAFLD). Unfortunately, it is often challenging to assess inflammation in NAFLD due to its dynamic nature...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B

Liang LY, Lee HW, Wong VWS, Yip TCF, Tse YK, Hui VWK, Lui GCY, Chan HLY, Wong GLH

Background/Aims: Serum fibrosis scores comprised of common laboratory tests have high utility to assess severity of liver fibrosis. We aimed to derive and validate a hepatocellular carcinoma (HCC) risk score...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases

Lin H, Wong GLH, Zhang X, Yip TCF, Liu K, Tse YK, Hui VWK, Lai JCT, Chan HLY, Wong VWS

Background/Aims: We aimed to determine the association between blood urea level and incident cirrhosis, hepatic decompensation, and hepatocellular carcinoma in chronic liver disease (CLD) patients. Methods: The association between blood urea...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment

Yap DYH, Liu KSH, Hsu YC, Wong GLH, Tsai MC, Chen CH, Hsu CS, Hui YT, Li MKK, Liu CH, Kan YM, Yu ML, Yuen MF

Background/Aims: Data on treatment efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) for chronic hepatitis C virus (HCV) infection in Asian patients with severe renal impairment are limited. This study aimed to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr